Aspivix

Focus: Aspivix is a Swiss biotech focused on tenaculum alternatives for gynecological procedures, particularly IUD insertion. The company operates at pre-revenue stage with a highly specialized, niche medical device focus.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Aspivix

AI assessmentNot Hiring

No open roles listed right now. Follow Aspivix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Carevix

IUD

N/A

Clinical Trials (1)

NCT07290517Assessing Pain and Effectiveness of Carevix Device for IUD Insertions

N/A

Help build intelligence for Aspivix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape a nascent company from ground level with only 3 active job openings, suggesting selective, high-impact hiring
Specialized focus on gynecological innovation addresses an underserved clinical need in IUD insertion procedures
Early-stage Swiss biotech offers potential equity upside and entrepreneurial environment before revenue generation

Watch Out For

Pre-revenue status with no disclosed funding creates severe financial stability risk and unclear runway
Minimal pipeline visibility: only 3 trials across 2 programs with no published data or clinical readouts reported
Extremely limited hiring (3 roles, all Sales) suggests either resource constraints or lack of near-term execution plans

Generated by Claude from Aspivix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Traction of the cervix for IUD insertion

IUD Insertion

N/A

Clinical Trials (1)

NCT04441281Usability, Safety and Efficacy of AspivixTM (Comparative Study)

N/A

cervical vacuum tenaculum

IUD Insertion

N/A

Clinical Trials (1)

NCT04441333Usability, Safety and Efficacy of AspivixTM

N/A